(Reuters) -Telehealth firm Hims & Hers Health said on Tuesday it plans to sell Eli Lilly's diabetes and weight-loss drugs on ...

Teladoc (TDOC) closed at $7.79 in the latest trading session, marking a +0.39% move from the prior day. The stock lagged the S&P 500's daily gain of 0.67%. On the other hand, the Dow registered a gain ...

Mitsubishi UFJ Trust & Banking Corp lifted its holdings in Teladoc Health, Inc. (NYSE:TDOC – Free Report) by 1,363.0% in the ...

Teladoc Health (NYSE:TDOC) experienced a 10% decline in share price over the past week, despite announcing significant expansions in its connected care partnerships and pharmacy integration agreements ...

Bullish option flow detected in Teladoc (TDOC) with 7,109 calls trading, 1.3x expected, and implied vol increasing almost 2 points to 78.51%.

Hims & Hers is expanding access to Eli Lilly's branded weight loss drug Zepbound and diabetes drug Mounjaro as well as ...

Two AI healthcare stocks -- Recursion Pharmaceuticals ( RXRX -2.76%) and Teladoc Health ( TDOC -5.20%) -- have lagged the ...

Despite the still positive FCF generation and richer balance sheet, it remains to be seen when Teladoc's growth may ...

Telemedicine specialist Teladoc Health (NYSE: TDOC) has been a terrible investment over the past three years. Once the company's pandemic-fueled business boom cooled down, its revenue and visit growth ...

Shares of Teladoc Health, Inc. (NYSE:TDOC – Get Free Report) have been assigned an average rating of “Hold” from the eighteen ...

Teladoc (TDOC) reachead $8.64 at the closing of the latest trading day, reflecting no change compared to its last close.

Teladoc Health Inc. investors can’t proceed with a proposed class action alleging the online health company misrepresented ...